NICE Declines to Recommend Cabometyx for Thyroid Cancer Treatment
April 6, 2023
In a new draft guidance, the UK’s National Institute for Health and Care Excellence (NICE) decided against recommending Ipsen’s small molecule drug Cabometyx (cabozantinib) for the treatment of differentiated thyroid cancer (DTC). The recommendation comes after approval for the indication was made last year.
According to Emily Kimber, “NICE noted that Cabometyx has been shown to increase how long patients have before the disease gets worse, but said it is not clear if it increases how long people live, meaning cost-effectiveness estimates are ‘unclear’.”
To read more, click here.
(Source: PM Live, April 6th, 2023)